newsfilter
← Latest News
GlobeNewswire·

Kura Oncology Reports First Quarter 2026 Financial Results

– $5.8 million in KOMZIFTI™ (ziftomenib) net product revenue in first full quarter of commercialization – – Robust new patient starts and early launch dynamics, including repeat use, switching and combination